As part of cost-cutting measures across the federal government, the Trump administration last month instituted a new National ...

New findings published today in NEJM Evidence reveal promising clinical outcome for Cellenkos Inc.'s cryopreserved, ...

Overnight, and to my surprise, I became the face of research at Harvard. But my daughter’s text was not the only surprise I ...

Single and multi-dose studies of the small molecule TREM2 agonist VG-3927 clear early safety hurdle. Meanwhile, new findings ...

Qure's AMT-130 shows 80% Huntington's Disease progression slowing. Click to read more on QURE's financially strong, advancing ...

Biogen is seeking approval for tofersen based on its effects on a neurofilament biomarker that it says is ... In tofersen's favour is that SOD1-ALS has a devastating impact on patients, with ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, ...

2025 — Scientists say they have discovered how a group of proteins linked to Parkinson's disease and amyotrophic lateral sclerosis act as 'guardians' of mitochondria, small organelles ...

Recreational Activities Such as Golfing, Gardening May Be Associated With Increased ALS Risk Among Men Mar ... blood tests reveal elevated NfL, a biomarker of nerve damage, could see worsening ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...